Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase III study.
In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.
